


This promotional meeting is fully sponsored and organised by Astellas, including speaker honoraria and production of materials, and may include promotional messages related to an Astellas product.



This is intended for healthcare professionals only

ASTELLAS SPONSORED SYMPOSIUM AT THE UKOF 2026 ANNUAL CONGRESS

# ADVANCING FIRST-LINE CARE IN ADVANCED UROTHELIAL CANCER: FROM EVIDENCE TO UK PRACTICE

10:30–11:30 | Thursday 11 June 2026 | Ripley Suite (Crowne Plaza Harrogate)

Session	Timings
<b>Welcome and introductions</b> Dr Will Ince	5 mins
<b>EV302 Data &amp; Safety</b> Dr Will Ince	10 mins
<b>EV302 Subgroup update</b> Dr Hilary Glen	10 mins
<b>EV302 Subgroup case studies</b> All panellists, chaired by Dr Akash Maniam	30 mins
<b>Q&amp;A</b> All panellists	5 mins

## Indications:<sup>1</sup>

- PADCEV, in combination with pembrolizumab, is indicated for the 1L treatment of adult patients with u/mUC who are eligible for platinum-containing chemotherapy.
- PADCEV as monotherapy is indicated for the treatment of adult patients with locally advanced or mUC who have previously received a platinum-containing chemotherapy and a Programmed cell death protein 1/ligand 1 or programmed death-ligand 1 inhibitor.



The above QR code takes you to the PADCEV Prescribing Information

Additional risk minimisation measures are associated with PADCEV. Please consult the electronic medicines compendium (eMC) website and direct your patients to the Patient Card available in the product packaging. Prescribing Information is available via the QR code or at: [https://dhgd52pup2eiv.cloudfront.net/23ffe42b-4e89-48e1-b8d8-08b726ed94c1/b5d6cdf5-d05a-4bb1-9965-de9a244d39eb/b5d6cdf5-d05a-4bb1-9965-de9a244d39eb\\_source\\_v.pdf](https://dhgd52pup2eiv.cloudfront.net/23ffe42b-4e89-48e1-b8d8-08b726ed94c1/b5d6cdf5-d05a-4bb1-9965-de9a244d39eb/b5d6cdf5-d05a-4bb1-9965-de9a244d39eb_source_v.pdf)

1L, first line; m, metastatic; u, unresectable; UC, urothelial carcinoma.  
1. PADCEV™ (enfortumab vedotin) Summary of Product Characteristics.

Date of preparation: May 2026 | MAT-GB-PAD-2026-00157

Adverse events should be reported. Reporting forms and information can be found at [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard) or search for 'MHRA yellow card' in the Google Play Store or Apple App Store. Adverse events should also be reported to Astellas Pharma Ltd on 0800 783 5018.

